EIDC Toolboxes
Anthrax | AR/AMR | Influenza | Fungi | MMR | Parasites | Polio | Pox | Prions | SARS-CoV-2 | VHF | Waterborne Diseases | Zika | Other Zoonotic Agents
4/3/2024
Share/Suggest a ResourceQuestions, Comments, Suggestions? Leave Feedback.
Anthrax | AR/AMR | Influenza | Fungi | MMR | Parasites | Polio | Pox | Prions | SARS-CoV-2 | VHF | Waterborne Diseases | Zika | Other Zoonotic Agents
Share/Suggest a ResourceQuestions, Comments, Suggestions? Leave Feedback.
Chapter 3- Includes Safety procedures for incoming clinical samples.
Third edition, June 2018
Baldo A, Galanis E, Tangy F, Herman P.
The use of recombinant MV vector has to comply with various regulatory requirements, particularly relating to the assessment of potential risks for human health and the environment. The present article highlights the main characteristics of MV and recombinant MV vectors used for vaccination and virotherapy and discusses these features from a biosafety point of view.